Disc Medicine Inc IRON

$80.00 -3.23 (-3.88%)

Valuation

Market cap
319,153,000
Revenue TTM
$0
Net income TTM
$-212,180,000
P/E (trailing)
0.00
P/E (forward)
—
Profit margin
0.00%
Debt to equity
0.09

Trading

Volume
779,900
Avg volume
1,055,856
Day's range
$79.73 – $83.00
Shares out
3,835,000
Stochastic %K
29%
Beta
0.96
Analysts
Strong Buy
Price target
$124.46

Price

Company profile

Disc Medicine, Inc., together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases in the United States. The company has assembled a portfolio of clinical and preclinical product candidates that aim to modify fundamental biological pathways associated with the formati...

Show more

Disc Medicine, Inc., together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases in the United States. The company has assembled a portfolio of clinical and preclinical product candidates that aim to modify fundamental biological pathways associated with the formation and function of red blood cells, primarily heme biosynthesis and iron homeostasis. Its pipeline includes bitopertin for the treatment of erythropoietic porphyrias, including erythropoietic protoporphyria, X-linked protoporphyria, and diamond-blackfan anemia; DISC-0974 for the treatment of anemia of myelofibrosis, and anemia of chronic kidney disease; and DISC-3405 for the treatment of polycythemia vera, and other hematologic disorders. It also develops preclinical programs include DISC-0998, for the treatment of anemia associated with inflammatory diseases. The company was founded in 2017 and is headquartered in Watertown, Massachusetts.

Industry
Biotechnology
Sector
Healthcare
Phone
617 674 9274
Website
https://www.discmedicine.com
Address
321 Arsenal Street, Suite 101, Watertown, United States

Latest news

Stocktwits

S_Franconi Nov 11, 2:40 PM
$IRON 534 Watchers 11/11/26
0 replies
Merlintrader Nov 10, 10:37 PM
$IRON Disc Medicine (IRON): cash $682.8M, runway into 2030 after offering Free weekly catalyst newsletter: https://merlintrader.beehiiv.com/p/week-ahead-10-catalysts-we-re-watching-november-9-13 Not investment advice.
0 replies
Merlintrader Nov 9, 7:45 PM
$IRON Disc Medicine Files Prospectus for Up to $189,925,765 Common Stock Offering (Nov 5) • Disc Medicine entered a sales agreement with TD Cowen for at-the-market sales of common stock. • Shares with an aggregate gross sales price of up to $189,925,765 may be sold from time to time. • Upcoming: Conference presentation — Dec 12, 2026 • Multiple portfolio presentations are planned at the ASH Annual Meeting in New Orleans on December 12–15, 2026. Full hub (catalysts, filings & latest news): https://www.merlintrader.com/disc-medicine-stock-hub?utm_source=stocktwits&utm_medium=social&utm_campaign=st-hub-giro&utm_content=iron Free weekly catalyst newsletter — no free trials, no logins, FREE is FREE: https://merlintrader.beehiiv.com/subscribe?utm_source=stocktwits&utm_medium=social&utm_campaign=st-hub-giro&utm_content=iron Not investment advice.
0 replies
Quantumup Nov 9, 11:23 AM
Guggenheim🏁 $IRON Buy-$132 and said--Disc Medicine, Inc. (IRON) offers a portfolio of de-risked disease-modifying treatments for serious blood disorders by targeting heme biosynthesis and iron regulation, implying significant commercial synergies. [CULV, LEO Pharma, Boeringer, BMY GSK INCY] Guggenheim went on to say: https://x.com/Quantumup1/status/2119752538199142401?a=Xixgh4sg5VIeeC176HM&s=20
1 replies
GTA_Terminal Nov 8, 8:36 PM
Dark pool check on $IRON: what traded off the exchanges in the latest session. Price barely moved (+0.6%), which is what you'd expect if somebody big is building or unwinding a position quietly. Look up any stock's options flow and dark pools on the GTA Terminal, free for 7 days: https://globaltradersacademy.com/start-trial?a=stocktwits&sym=IRON&utm_source=stocktwits&utm_medium=social&utm_campaign=trial&utm_content=IRON Read the full article for the full details: https://globaltradersacademy.com/articles/dark-pool-check-disc-medicine-iron?utm_source=stocktwits&utm_medium=social
0 replies
Merlintrader Nov 6, 9:11 PM
$IRON #Biotech #FDA — Disc Medicine reported $682.8M of September cash and marketable securities, before its October financing proceeds. Bitopertin’s APOLLO data, NDA resubmission and FDA review remain the key regulatory drivers. https://www.merlintrader.com/disc-medicine-stock-hub/
0 replies
BiotechSwings Nov 6, 1:01 AM
December is doing the talking for $IRON imo ASH Dec 12 to 15 brings fresh DISC 3405 data, updated RESTORE PV in polycythemia vera plus first sickle cell data. bitopertin already cleared its big test, APOLLO hit every endpoint in October, PPIX down 41.4% vs placebo in 183 patients, and the NDA goes back in by year end Q3 beat this morning, minus 1.53 vs minus 1.63 expected, and the stock still closed near 78.47, down about 6% on a day the sector bled about 7%
0 replies
Merlintrader Nov 5, 6:01 PM
$IRON : Disc Medicine Q3 2026 and APOLLO (reported Nov 5): APOLLO Phase 3 bitopertin met all primary and secondary endpoints (Oct 19 topline; restated Nov 5); cash, equivalents and marketable securities $682.8M at Sept 30, before ~$485.9M net October offering proceeds; runway guided into 2030; Bitopertin NDA resubmission planned by year-end 2026; FDA decision anticipated mid-2027; Q3 net loss about $59M. Questions worth checking: What is the next catalyst for IRON stock? How much cash does Disc Medicine have? Is Disc Medicine’s bitopertin FDA approved? Answers, primary sources and downloadable PDF report in our hub: https://www.merlintrader.com/disc-medicine-stock-hub/?utm_source=stocktwits&utm_medium=social&utm_campaign=iron_hubpdf_nov26 Not investment advice.
0 replies